In another phase Ib study (NCT02374645), the clinical evaluation of savolitinib plus gefitinib (a first-generation EGFR-TKI) demonstrated promising anti-tumor activity with acceptable safety profile in EGFRm, MET-amplified advanced NSCLC patients from China who had disease progression on EGFR-TKIs. Here, MET is linked to neoplasm.